Price movement over the last 24 hours
Alcon AG vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Alcon AG trades at $66.93 (market cap $32.69B), while Direxion Daily Semiconductor Bull 3X Shares trades at $174.2. The key difference: Alcon AG pays a 0.54% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none, and Direxion Daily Semiconductor Bull 3X Shares is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | SOXL | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.22 | $300.77 |
52-Week Low | $62.02 | $23.99 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
SOXL, a 3x leveraged semiconductor ETF, trades at $194.65, up 7.26% in 24 hours but remains in a bearish technical trend. Recent volatility includes a 16% single-day drop on July 1, 2026 (24/7 Wall Street), highlighting risks of leveraged decay. News sentiment is mixed, with JPMorgan advocating buying the chip dip while Morgan Stanley notes investor rotation away from semiconductors. Key support lies at $189, with resistance at $200.
Outlook is highly speculative due to leverage amplifying sector swings. Opportunities exist for tactical traders betting on semiconductor rebounds, but risks of rapid decay in choppy markets are severe. Long-term holders face structural erosion from volatility, making SOXL unsuitable for buy-and-hold strategies amid elevated sector uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →